Pulmonary veno-occlusive disease (PVOD) is a rare but serious condition characterized by pulmonary vein occlusion, which leads to impaired blood flow from the lungs and subsequent increase in pressure in the pulmonary artery. The main mechanism of PVOD pathogenesis is associated with the formation of blood clots or stenosis (narrowing) of the pulmonary veins, which often causes right ventricular failure. Symptoms of the disease can vary from shortness of breath and wheezing to severe cyanosis and cardiovascular failure. The pathology most often manifests itself in young and middle-aged people and requires timely diagnosis and treatment, since untimely intervention can lead to serious consequences for the health of patients.
History of the disease and interesting historical facts
The history of pulmonary veno-occlusive disease goes back several decades. The first mentions of the disease date back to the mid-20th century, when in the 1960s, active research into the causes of pulmonary hypertension began. In 1966, doctors from Boston, USA, first described a complex of symptoms associated with pulmonary vein occlusion. Research has shown a link between PVOD and systemic diseases such as scleroderma and diseases causing thrombosis. Throughout the 1970s and 1980s, scientists continued to study the etiology and pathophysiology of the disease, which contributed to a deeper understanding of the role of the pulmonary veins in the development of pulmonary hypertension. Notably, the presence of PVOD can be associated with certain environmental factors, such as long-term exposure to toxic substances, which emphasizes the importance of a comprehensive analysis of the impact of ecology on lung health.
Epidemiology
The epidemiology of pulmonary veno-occlusive disease is quite specific, with an estimated prevalence of 2-5 cases per million people per year. However, this figure may vary depending on the geographic region and the presence of predisposing factors such as blood disorders. Most cases occur in young adults between the ages of 20 and 40, but cases have been reported in older patients. Studies show that PVOD has a higher prevalence in patients with certain comorbidities such as systemic lupus erythematosus and chronic liver disease, indicating the need for closer monitoring of this group.
Genetic predisposition to this disease
Genetic predisposition to PVOD is being studied to determine whether multiple mutations and genes are involved. Some studies have suggested a link between the disease and mutations in genes involved in hemostasis, such as F2 (prothrombin genes) and F5 (von Willebrand factor genes). These genetic abnormalities may increase the risk of thrombosis. However, it should be noted that not all cases of PVOD can be identified as having a genetic predisposition, suggesting that the disease is multifactorial. Research in this area continues to evolve, highlighting the importance of further understanding the molecular biology and genetics of lung disease.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of pulmonary veno-occlusive disease, including both physical and chemical ones. The main factors include:
- The presence of systemic diseases such as scleroderma or the painful form of Ehlers-Danlos syndrome.
- Long-term exposure to toxic substances, such as asbestos or certain heavy metals.
- Cryptogenic pulmonary fibrosis, which can lead to changes in the structure of the pulmonary veins.
- History of thrombosis and venous thromboembolism in the patient or his close relatives.
- Inactive lifestyle and obesity.
Each of these factors can have a significant impact on the risk of developing PVOD, and their combination can increase the likelihood of the disease.
Diagnosis of this disease
Diagnosis of pulmonary veno-occlusive disease is a set of measures aimed at identifying this pathology. The main symptoms that doctors pay attention to include:
- Progressive shortness of breath that worsens with physical exertion.
- DSO (dyspnoea status occlusion) and pleuritic pain.
- Bluish discoloration of the skin and mucous membranes.
- Symptoms of right ventricular failure, including swelling of the lower extremities.
Laboratory tests may include blood tests to check for thrombus formation and a coagulogram. Radiological tests usually include a chest CT scan, which allows visualization of occluded veins. Other diagnostics may include pulmonary angiography. Differential diagnosis is important to exclude other causes of pulmonary hypertension, such as pulmonary arterial hypertension, polycythemia, etc.
Treatment
Treatment of pulmonary veno-occlusive disease may involve different approaches depending on the stage of the disease and the patient’s condition. General principles of treatment are to improve blood flow and reduce pressure in the pulmonary veins. Pharmacological treatment may include anticoagulants such as warfarin and dexamethasone to reduce inflammation. Surgical treatment may require removal of occluded veins or implantation of a special reduction device to normalize venous outflow. Thrombolysis methods may also be used in acute cases. In addition, non-pharmacological approaches such as physical rehabilitation and diet therapy may help improve the overall health of patients.
List of medications used to treat this disease
Among the medications that may be prescribed to patients with pulmonary veno-occlusive disease are:
- Warfarin (anticoagulant).
- Dexamethasone (corticosteroid).
- Ipratropium (bronchodilator).
- Silidrom (antihypertensive drug).
- Acetazolamide (a diuretic to relieve swelling).
Disease monitoring
Monitoring the health of patients with pulmonary veno-occlusive disease includes regular examinations to control respiratory function and pulmonary hypertension dynamics. The main control stages are echocardiography and CT to assess the condition of the pulmonary artery and veins. The prognosis for patients receiving adequate treatment can be relatively favorable, although there is still a risk of complications such as thrombosis and right ventricular failure. A comprehensive approach to monitoring allows for treatment adjustments and an improvement in the patient's quality of life.
Age-related features of the disease
The incidence of pulmonary veno-occlusive disease may vary in different age groups. In young people, the disease is often associated with hereditary influences, while in older patients it may be caused by concomitant diseases and thrombus formation. In childhood, cases of PVOD are extremely rare, and in the elderly, chronic pulmonary changes often occur, which can aggravate the course of the disease. Different age groups require an individual approach to diagnosis and treatment, taking into account the characteristics of the body.
Questions and Answers
- What are the main symptoms of pulmonary veno-occlusive disease? The main symptoms include shortness of breath, wheezing, cyanosis of the skin and swelling of the lower extremities.
- How to diagnose LVOD? Diagnosis is made using laboratory tests, X-rays, CT and angiopulmonography.
- Which treatment is most effective? Treatment includes anticoagulant therapy, corticosteroids, and in severe cases, surgery may be required.
- What are the risk factors for developing the disease? Risk factors include the presence of systemic diseases, thrombosis, and long-term exposure to toxic substances.
- What is the prognosis for patients with LVOD? The prognosis depends on timely treatment and individual characteristics of the patient, however, with adequate therapy it can be quite favorable.
